New Report “Artificial intelligence for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020”

Deep Pharma Intelligence

Deep Pharma Intelligence

Interactive mindmaps showing Pharmaceutical AI ecosystem at a glance

Interactive mindmaps showing Pharmaceutical AI ecosystem at a glance

Report by Deep Pharma Intelligence covers 240+ biotech companies, 600+ investors, 90+ corporations, and 35 R&D centers in pharmaceutical AI sector

LONDON, UK, November 27, 2020 /EINPresswire.com/ — Deep Pharma Intelligence announces the release of a new, open-access 130-page analytical Report and interactive analytics Dashboard: “AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020”. This resource delivers advanced market intelligence, interactive mindmaps, benchmarking for companies, investors and technologies, competitive and SWOT analysis through the interactive IT-Platform and Big Data analytical Dashboard. The current release includes insights about 240+ biotech companies, 600+ investors, 90+ pharma corporations, and 35 R&D centers in the area of pharmaceutical and healthcare artificial intelligence (AI).

Based on the analysis of the key players and overall industry dynamics, our team identified a number of key trends and insights about the investment landscape, R&D collaborations, AI application use cases, and more. Some of the key takeaways include the following conclusions:

1) the segment of pharmaceutical AI continues consolidation;
2) pharmaceutical AI sector is “heating up” for investments;
3) big pharma and contract research organizations increasingly compete for AI partnerships;
4) the sector of pharmaceutical AI is maturing for a likely wave of IPOs and M&As in 2021-2022;
5) COVID-19 pandemics appears to be a positive catalyst for the acceleration of the AI adoption

The report and the analytics dashboard are powerful tools for strategic insights, opportunity evaluation, competitor profiling, and other goals, relevant to pharma and biotech decision-makers, Life Science investors, consulting companies, and regulatory agencies.

The 130-page open-access report and the underlying IT-platform marks the 9th installment in a series of reports on the topic of the artificial Intelligence application in pharmaceutical research that Deep Pharma Intelligence has been producing since 2017. The central aim of this series of special case studies is to provide a comprehensive overview of the industry landscape and try to predict what is coming next.

The report “Artificial intelligence (AI) for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020” and the underlying IT-platform and analytics Dashboard mark the inaugural project of Deep Pharma Intelligence Ltd., a new joint venture of Deep Knowledge Analytics Pharma Division and BPT Analytics (BiopharmaTrend), dedicated to producing powerful data mining and visualization systems, interactive analytics tools, and industry reports offering deep technical insights, business intelligence, and strategic guidance in the high growth and significant opportunity areas of the pharmaceutical industry, including AI in drug discovery, emerging therapeutic targets and drug modalities, new therapies and technologies, promising startups, and more.

The scope and purpose of Deep Pharma Intelligence is to establish itself as the leading entity focused on deep market and investment intelligence, due diligence, competitive research, company and technology benchmarking and industry trend prediction in highly disruptive areas of biopharmaceutical research and development, and healthcare tech. Its long-term strategic goal is to establish itself as a dominant player in the area of pharmaceutical investment, M&A, and strategic consulting by offering outstanding analytical capabilities, analytics software-as-a-service (SaaS) solutions, and other technological solutions for identifying business development and investment opportunities, technology scouting, R&D outsourcing, and building corporate growth strategies.

About Deep Pharma Intelligence
Deep Pharma Intelligence is a new joint venture of Deep Knowledge Analytics Pharma Division and BPT Analytics (BiopharmaTrend) producing specialized data mining and visualization systems, interactive analytics dashboards and industry reports offering deep technical insights, business intelligence, competitive analysis, industry benchmarking and strategic guidance in high growth and novel opportunity areas of the pharma sector, including AI in drug discovery, emerging therapeutic targets and drug modalities, new therapies and technologies, promising startups, and more.

About Deep Knowledge Analytics
Deep Knowledge Analytics is a DeepTech focused agency producing advanced analytics on DeepTech and frontier-technology industries using sophisticated multi-dimensional frameworks and algorithmic methods that combine hundreds of specially-designed and specifically-weighted metrics and parameters to deliver insightful market intelligence, pragmatic forecasting and tangible industry benchmarking.

About BPT Analytics (BiopharmaTrend)
BiopharmaTrend is a specialized provider of analytics, market intelligence, articles, opinions, commentaries, and interviews on the pharmaceutical and healthcare industries with a particular focus on data and digital tech and emerging R&D trends. They are currently developing sophisticated data mining and knowledge mapping platform focused on the biopharmaceutical industry, including data about companies, research collaborations, funding rounds, news, trends, research articles, patents, clinical trials, and other important data elements.

For press and media inquiries, please contact: info@deep-pharma.tech

Andrii Buvailo
BPT Analytics Ltd
info@biopharmatrend.com


Source: EIN Presswire

Private Jet Card Comparisons Enables Private Aviation Users To Compare 250 + Jet Card and Membership Options in Minutes

Private Jet Card Comparisons' easy-to-use filters enable subscribers to compare aircraft options, service area, safety, flight pricing, and details that matter

Our database is not duplicated anywhere. By compiling over 20,000 data points into a single, easy-to-use Excel spreadsheet, we make comparing easy. Subscribers see first-hand how offerings differ.”

— Doug Gollan, Editor, Private Jet Card Comparisons

MIAMI, FLORIDA, UNITED STATES, November 27, 2020 /EINPresswire.com/ — Private Jet Card Comparisons makes finding the best private aviation solutions fast and easy.

The independent online buyer's guide, launched in 2017, has compiled a proprietary database of over 250 jet card programs and memberships subscribers can compare by more than 65 variables that impact the offerings that best fit their flying needs. It has been updated 54 times since the beginning of the year.

By compiling comprehensive data in one place, Private Jet Card Comparisons has reduced research time from hours and days to just minutes.

"Our database is not duplicated anywhere else. By compiling the data into a single, easy-to-use Excel spreadsheet, we make comparing easy. Most of all, the entire process is transparent as subscribers can see first-hand how providers and programs offerings differ," said Doug Gollan, Founder and Editor-in-Chief of Private Jet Card Comparisons. "What's more, we constantly update the data. Just this year, we've made 54 updates based on changes to program policies."

A selection of what subscribers can compare includes:

Safety – Aircraft and Operator Sourcing Standards, and Pilot Experience
Pricing – Purchase Price, Hourly Rates, and Pricing Methodology
Flexibility – Lead time for Reservations and Cancellations, Applicable Aircraft, Seating Capacity, and Service Area
Stability – Ownership, Company History, Headcount, Refund Options, and Escrow Account Options
Aircraft Type – Search by Cabin Category, Specific Aircraft Type, or Seating Capacity, including the ability to upgrade or downgrade based on your needs for that trip
Details That Matter – Insurance, WiFi, Pets Policies, Unaccompanied Minors, Service Recovery, Initiation Fees, Annual and Monthly Dues, CPI Escalators, Fuel Surcharges, De-icing, and Peak Day Charges, Taxi Time, Segment, and Daily Minimums, Roundtrip Discounts

For subscribers who wish, there is both online and phone assistance. Additionally, they can use the VIP JET CARD DECIDER tool. Based on their input, Private Jet Card Comparisons will prepare a personalized analysis of the best options, including on-demand charter, jet cards, and memberships, and fractional ownership. The service includes a follow-up discussion on request.

Subscribers who pay $250 for 12 months of unlimited access also receive the website's BEST PRIVATE JET CHARTER BROKERS Guide, which includes a vetted list of on-demand brokers, including ratings from third-party consumer review websites and professional certifications.

A free newsletter and daily news and insights are available to all visitors to Private Jet Card Comparisons.

"Our only goal is to help private aviation users figure out the best ways to access private travel and identify the providers and programs that best fit their needs," said Gollan.

Private Jet Card Comparisons is the only private aviation solutions comparison website that does not sell user contact information or accept lead referral fees from jet companies, ensuring both privacy and that subscribers receive unbiased data and advice.

Douglas Gollan
Private Jet Card Comparisons
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Vigna Law Group: Deep Tissue Injury (DTI)…What Comes Next? Litigation

Dr. Greg Vigna

Dr. Greg Vigna

VLG a national neurological injury and malpractice injury law firm, offers immediate evaluation of hospital acquired bed sores from photo review by an expert.

As a practicing physician in hospitals across the country, I have seen hospital employed nurses who are scared to call a wound a Grade III decubitus ulcer since that is a ‘reportable event’…”

— Dr. Greg Vigna

CALIFORNIA, UNITED STATES, November 27, 2020 /EINPresswire.com/ — Greg Vigna, MD, JD, a physician Board Certified in Physical Medicine and Rehabilitation, practicing physician, and national medical malpractice and pharmaceutical injury attorney comments:

“Too often hospitals and nursing homes in their initial assessment of a newly identified wound misdiagnose the grade of a decubitus ulcer and are slow to react to prevent further soft tissue damage. The grading system for decubitus ulcers describes the depth of a wound but that has no correlation to how a wound occurs. The pathophysiology of a decubitus ulcer is pressure and the tissue most sensitive to pressure is muscle so the muscle dies prior to injury and breakdown of the skin and the skin will eventually breakdown because the underlying tissue is necrotic or dead. Deep tissue injury (DTI) means that it is impossible to determine the depth of a wound since there is bruising under the intact skin reflecting damage, but the true extent of injury is unknown as wounds take 2-4 weeks to declare themselves. With proper wound care and pressure relief (taking pressure off the wound) some of these DTIs turn out to be insignificant because the tissue is injured but not irreversibly dead.

As a practicing physician in hospitals across the country, I have seen hospital employed nurses who are scared to call a wound a Grade III decubitus ulcer since that is a ‘reportable event’ to state authorities so there is a delay in proper management.

Often simply ordering a clinitron bed may prevent further tissue loss in a patient who turning off the wound is difficult or sometimes impossible."

Where is the Clinitron Bed?: https://vignalawgroup.com/2020/03/24/wheres-the-clinitron-bed-decubitus-ulcers-care/

Dr. Vigna has previously provided care as a wound care medical director of tertiary referral wound care program at a LTAC in Northern Louisiana and managed patients referred from as far as New Orleans, Texas, Arkansas, and Mississippi and have directed the care in over 300 patients who required flap closure of Grade III and Grade IV decubitus ulcers, many of them occurred in nursing homes and hospital. He has provided expert testimony for decubitus ulcers cases and has represented patients as an attorney who have suffered this “Never Event” and litigated decubitus ulcer cases to successful conclusion with national malpractice injury law firms across the country.

Dr. Vigna is a California and Washington DC lawyer who focuses on catastrophic neurological injuries caused by transvaginal mesh devices and injuries caused by physician, hospital, and nursing home malpractice. He has clients serious injuries filed around the country with Martin Baughman, a Dallas Texas firm. Ben Martin and Laura Baughman are national pharmaceutical and personal injury trial attorneys in Dallas, Texas.

To learn more on the anatomical basis for TOT injury or irritation to the obturator and pudendal nerve and the treatments of obturator and pudendal neuralgia visit our website: https://vignalawgroup.com/ebooks/pelvic-mesh-pain/#page=59

Click here for a FREE BOOK on Vaginal Mesh Pain.
For articles, video resources, and information visit the Pudendal Neuralgia Educational Portal or https://tvm.lifecare123.com/.
Click here for information regarding sling related complications.

Greg Vigna
Greg Vigna, M.D., J.D.
+1 800-761-9206
gavmdjd@gmail.com
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Veterinary Healthcare Market 2020, Global Industry Analysis, Size, Share, Growth, Trends and Forecast – 2025

A New Market Study, titled “Veterinary Healthcare Product Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports.

PUNE, MAHARASTRA, INDIA, November 27, 2020 /EINPresswire.com/ — Summary

A New Market Study, titled “Veterinary Healthcare Product Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports.

This report provides in depth study of “Veterinary Healthcare Product Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Veterinary Healthcare Product Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

This market report offers a comprehensive analysis of the global Veterinary Healthcare Product market. This report focused on Veterinary Healthcare Product market past and present growth globally. Global research on Global Veterinary Healthcare Product Industry presents a market overview, product details, classification, market concentration, and maturity study. The market value and growth rate from 2019-2025 along with industry size estimates are explained.

Request a Free Sample Report @ https://www.wiseguyreports.com/sample-request/5504010-covid-19-impact-on-global-veterinary-healthcare-product

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
The major vendors covered:
Pfizer
Merck
Sanofi-Aventis
Bayer HealthCare
Virbac
Novartis
Boehringer Ingelheim
Heska Corporation
Bioniche Animal Health Canada, Inc.
Ceva
Johnson & Johnson
MedFly
Zoetis
3M
R. M. Hatcheries
Lomir Biomedical

Veterinary Healthcare Product market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Veterinary Healthcare Product market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Veterinary Healthcare Product market is segmented into
Vaccines
Paraciticides
Anti-infectives
Medicinal Feed Additives
Other

Segment by Application, the Veterinary Healthcare Product market is segmented into
Pet
Poultry
Other

Regional and Country-level Analysis
The Veterinary Healthcare Product market is analysed and market size information is provided by regions (countries).
The key regions covered in the Veterinary Healthcare Product market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

At Any Query @ https://www.wiseguyreports.com/enquiry/5504010-covid-19-impact-on-global-veterinary-healthcare-product

Major Key Points in Table of Content

1 Study Coverage
1.1 Veterinary Healthcare Product Product Introduction
1.2 Market Segments
1.3 Key Veterinary Healthcare Product Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Veterinary Healthcare Product Market Size Growth Rate by Type
1.4.2 Vaccines
1.4.3 Paraciticides
1.4.4 Anti-infectives
1.4.5 Medicinal Feed Additives
1.4.6 Other
1.5 Market by Application
1.5.1 Global Veterinary Healthcare Product Market Size Growth Rate by Application
1.5.2 Pet
1.5.3 Poultry
1.5.4 Other
1.6 Coronavirus Disease 2019 (Covid-19): Veterinary Healthcare Product Industry Impact
1.6.1 How the Covid-19 is Affecting the Veterinary Healthcare Product Industry
1.6.1.1 Veterinary Healthcare Product Business Impact Assessment – Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Veterinary Healthcare Product Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Veterinary Healthcare Product Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

….

11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Description, Business Overview and Total Revenue
11.1.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Pfizer Veterinary Healthcare Product Products Offered
11.1.5 Pfizer Recent Development
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Description, Business Overview and Total Revenue
11.2.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Merck Veterinary Healthcare Product Products Offered
11.2.5 Merck Recent Development
11.3 Sanofi-Aventis
11.3.1 Sanofi-Aventis Corporation Information
11.3.2 Sanofi-Aventis Description, Business Overview and Total Revenue
11.3.3 Sanofi-Aventis Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Sanofi-Aventis Veterinary Healthcare Product Products Offered
11.3.5 Sanofi-Aventis Recent Development
11.4 Bayer HealthCare
11.4.1 Bayer HealthCare Corporation Information
11.4.2 Bayer HealthCare Description, Business Overview and Total Revenue
11.4.3 Bayer HealthCare Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Bayer HealthCare Veterinary Healthcare Product Products Offered
11.4.5 Bayer HealthCare Recent Development
11.5 Virbac
11.5.1 Virbac Corporation Information
11.5.2 Virbac Description, Business Overview and Total Revenue
11.5.3 Virbac Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Virbac Veterinary Healthcare Product Products Offered
11.5.5 Virbac Recent Development
11.6 Novartis
11.6.1 Novartis Corporation Information
11.6.2 Novartis Description, Business Overview and Total Revenue
11.6.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Novartis Veterinary Healthcare Product Products Offered
11.6.5 Novartis Recent Development
11.7 Boehringer Ingelheim
11.7.1 Boehringer Ingelheim Corporation Information
11.7.2 Boehringer Ingelheim Description, Business Overview and Total Revenue
11.7.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Boehringer Ingelheim Veterinary Healthcare Product Products Offered
11.7.5 Boehringer Ingelheim Recent Development
11.8 Heska Corporation
11.8.1 Heska Corporation Corporation Information
11.8.2 Heska Corporation Description, Business Overview and Total Revenue
11.8.3 Heska Corporation Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Heska Corporation Veterinary Healthcare Product Products Offered
11.8.5 Heska Corporation Recent Development
11.9 Bioniche Animal Health Canada, Inc.
11.9.1 Bioniche Animal Health Canada, Inc. Corporation Information
11.9.2 Bioniche Animal Health Canada, Inc. Description, Business Overview and Total Revenue
11.9.3 Bioniche Animal Health Canada, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Bioniche Animal Health Canada, Inc. Veterinary Healthcare Product Products Offered
11.9.5 Bioniche Animal Health Canada, Inc. Recent Development
11.10 Ceva
11.10.1 Ceva Corporation Information
11.10.2 Ceva Description, Business Overview and Total Revenue
11.10.3 Ceva Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Ceva Veterinary Healthcare Product Products Offered
11.10.5 Ceva Recent Development
11.1 Pfizer
11.12 MedFly
11.13 Zoetis
11.14 3M
11.15 R. M. Hatcheries
11.16 Lomir Biomedical

Continued….

Contact Us: sales@wiseguyreports.com

Ph: +1-646-845-9349 (US); Ph: +44 208 133 9349 (UK)

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349
email us here


Source: EIN Presswire

PACE-Approved Webcast Series Offers More Than Facelift

free dental team coaching service

More than the logo has changed at PracticePerfection!

Make every call and appointment with The Art of First Impressions

The Dental Profession’s Leading Telephone Skills Mastery Series

Dental Marketing Since 1989

Fully Customized, Transparent & Actionable Marketing Is Within Reach

Practice Perfection dental webcast series has a new look and more of the content dental practice owners and their teams want and need to thrive in today's world

Topics for 2021 range from techniques to call to appointments, real time, HIPAA-Compliant communications, Cause Marketing, Patient Testimonial Videos, Reviews Capture, no-show reduction & even IMPROV”

— Danile A. 'Danny' Bobrow

CHICAGO, IL, USA, November 27, 2020 /EINPresswire.com/ — Following a two year hiatus, the Practice Perfection https://www.PracticePerfection.com dental webcast series resumed monthly broadcasts in October of 2020.

"Frankly, running a successful dental marketing agency proved overwhelming during our restructuring" says Daniel A. 'Danny' Bobrow, MBA (finance), MBA (marketing), president of Chicago-based AIM Dental Marketing and Founder and Moderator of the series. "Now that our restructuring is largely complete, I have the pleasure and privilege of hosting key thought leaders on a wide range of subjects that are relevant for today's busy dental practice" concludes Bobrow who, along with his brother Michael Bobrow, DDS founded the American Dental Corporation in July of 1989.

Half of 2021 has already been scheduled. Topics range from techniques and services to convert telephone calls into scheduled appointments, platforms to ensure real time, HIPAA-compliant patient communications, leading edge fully integrated, cloud-based practice management software techniques and services to cross code medical and dental billing, protocols and services to adopt a fully integrated dental sleep medicine practice model, optimal cancer screening protocols, to interactive sessions to build team camaraderie.

December's webcast features World Series Champion and ring holder Jim Mecir.

Registrants have access to archived presentations by such medical and dental luminaries as Charles Blair, Chris Kammer, Brad Bale and Charles Whitney, MD, Martha Cortes, Bill Blatchford, Julian Holmes, Bill Domb, and many more (50 and counting).

Regular surveys ensure attendees hear from people on topics that are relevant to them.

To learn more contact Bobrow directly at 312-455-9488, ext. 301.

Daniel A. Bobrow
American Dental Corporation
+1 312-455-9488
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Biohacking Market 2020 Global Trend, Segmentation and Opportunities, Forecast 2027

WiseGuyReports.com adds “Global Biohacking Market Research Report 2020 Analysis and Forecast 2027” reports to its database.

PUNE, MAHARASTRA, INDIA, November 27, 2020 /EINPresswire.com/ — Biohacking Market:

Executive Summary

Biohacking is defined as the use of function-improving drugs or the utilization of internal or peripheral implants to enhance cognitive function, retention, and creativity in personalities. The most constructive method involves the consumption of nootropic drugs to improve intelligence and focus. Biohacking industry will observe a range of opportunities with the outbreak of the recent coronavirus disease. Remarkable developments are likely to be witnessed in the biohacking industry as a greater number of scientific communities’ resort to constant research to manage the widespread of the disease, which may strengthen the demand for biohacking solutions across the globe. Moreover, the escalating demand for smart devices and effective drugs, rising awareness for biohacking among forensic laboratories and pharmaceutical companies, and growing prevalence of chronic diseases among people are the few factors responsible for the CAGR of the market during the forecast period. According to the International Agency for Research on Cancer (IARC), globally, there were almost 18.1 million new cases of cancer and 9.6 million deaths caused by cancer reported in the year 2018. While the global burden of cancer is likely to reach almost 27.5 million new cancer cases and almost 16.3 million deaths affected through cancer by the year 2040. This, in turn, is likely to strengthen the demand for biohacking, thereby contributing to the market growth around the world. However, the lack of expertise as well as cyber security practices and stringent regulations concerning the genetic engineering experiments are the few factors limiting the market growth over the forecast period of 2020-2027.

Get Sample Copy of the Report @ https://www.wiseguyreports.com/sample-request/6071391-global-biohacking-market-size-study-by-product-smart

The regional analysis of the global Biohacking market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. Europe is the leading/significant region across the world in terms of market share owing to the rising government R&D investment for new drug discovery and development, along with the presence of significant number of market vendors in the region. Whereas Asia-Pacific is anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027. Factors such as the rise in prevalence of chronic diseases such as cancer, coupled with rapidly improving healthcare infrastructure in emerging nations, such as China and India, are the few factors creating a lucrative opportunity for the growth of the Biohacking market in the Asia-Pacific region.

Major market player included in this report are:
Apple Inc.
Fitbit, Inc.
The ODIN
Thync Global, Inc.
Synbiota Inc.
Moodmetric
HVMC, Inc.
InteraXon Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Smart Drugs
Sensors
Strains
Others

By End-User:
Forensic Laboratories
Pharmaceutical & Biotechnology Companies
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027

Target Audience of the Global Biohacking Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Continuous…

For further information on this report, visit – https://www.wiseguyreports.com/reports/6071391-global-biohacking-market-size-study-by-product-smart

NOTE : Our team is studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

NORAH TRENT
Wise Guy Reports
+162 825 80070
email us here


Source: EIN Presswire

Dr. David Samadi: ‘Movember’ reminds men early detection of prostate and testicular cancers saves lives

men’s health

"The Ultimate Manual " my recent book on Amazon is available with all secrets to longer and better life. The best gift of life is your health.

"The Ultimate Manual " my recent book on Amazon is available with all secrets to longer and better life. The best gift of life is your health.”

— Dr. David Samadi

NEW YORK, NEW YORK, UNITED STATES, November 27, 2020 /EINPresswire.com/ — For the year 2020, the American Cancer Society estimates more than 33,000 men will die from prostate cancer and over 400 men will die from testicular cancer. That’s why every year, November becomes ‘Movember,’ reminding men that the difference between early detection and late detection for prostate and testicular cancers can be life and death.

“I wholeheartedly agree, the earlier a cancer is caught, the better the survival rate,” exclaimed Dr. David Samadi, Director of Men’s Health and Urologic Oncology at St. Francis Hospital in Roslyn, New York. “As a prostate cancer surgeon who’s performed over 7,000 surgeries on men with prostate cancer and have cared for men with testicular cancer, finding these cancers early is key. That’s why educating men on knowing the signs and symptoms of each and seeing their urologist right away, can be a game changer in successfully beating these cancers back.”

During Movember, men are challenged to grow a moustache reminding men and women to take action for men’s health and well-being. Since its inception in 2003, the Movember movement has helped mobilize the funding of more than 1,250 innovative programs around the world geared towards helping men take control of their health and quality of life. These programs help bring awareness and fundraising for prostate and testicular cancers in addition to mental health and suicide prevention in men.

“Early detection has always been a key determinant for winning any cancer battle,” stated Dr. Samadi. “In the United States, prostate cancer is the second most commonly diagnosed cancer in men other than skin cancers. Beginning at age 40, men should talk to their doctor about PSA testing. Also pay attention to sexual and urinary changes such as difficulty achieving an erection or blood in urine or semen, which might be benign prostatic hyperplasia (BPH) or possibly prostate cancer. Any man with these changes should see their doctor to get an accurate diagnosis.”

Other signs and symptoms that might indicate prostate cancer include:
• Frequent urination, especially at night
• Difficulty starting urination or holding back urine
• Wear or interrupted flow of urine
• Frequent pain or stiffness in the lower back, hips, or upper thighs

“Testicular cancer has a high survival rate but some men may experience long-term treatment-related side effects affecting their quality of life,” explained Dr. Samadi. “This cancer is a disease of young men. Only 9 percent of men over age 50 are diagnosed with testicular cancer. Movember reminds men to do a monthly self-check of their testicles feeling for changes in the size or shape or any unusual lumps painful to the touch or not, get them checked out as soon as possible.”

Dr. Samadi reminds all men that prostate and testicular health matter and when men are informed, that’s when real progress is made in keeping men healthy and living longer.

To learn more about Movember, visit www.Movember.com

To learn more about Dr. Samadi’s recently released book, The Ultimate MANual, visit http://amzn.com/1735296902

Dr. David Samadi is the Director of Men’s Health and Urologic Oncology at St. Francis Hospital in Long Island. He’s a renowned and highly successful board certified Urologic Oncologist Expert and Robotic Surgeon in New York City, regarded as one of the leading prostate surgeons in the U.S., with a vast expertise in prostate cancer treatment and Robotic-Assisted Laparoscopic Prostatectomy. Dr. Samadi is a medical contributor to NewsMax TV and is also the author of The Ultimate MANual, Dr. Samadi’s Guide to Men’s Health and Wellness, available online both on Amazon and Barnes & Noble. Visit Dr. Samadi’s websites at robotic oncology and prostate cancer 911.

David Samadi
David Samadi
+1 3475330444
email us here

robotic prostate surgery


Source: EIN Presswire

Interview Released with Robert Vries, CEO at Hubrecht Organoid Technology speaker at 3D Cell Culture

P-340 Speaker Robert Vries

SMi Reports: Speaker interview released for SMi’s 5th Annual 3D Cell Culture taking place on 10–11 February 2021 as a virtual conference with online access only

LONDON, LONDON, UNITED KINGDOM, November 27, 2020 /EINPresswire.com/ — With SMi Group’s 3D Cell Culture returning for its 5th year on the 10th and 11th February 2021, as a virtual conference with online access only, the two-day conference is anticipated to have a closer look at various topics regarding developing complex physiologically relevant cell models in vitro.

SMi Group had the opportunity to speak with our key speaker Robert Vries, CEO at Hubrecht Organoid Technology for the conference, to discuss some of the challenges they face in the industry and their strategies for overcoming them.

Robert Vries received his PhD in Biochemistry from the Leiden University Medical Center on a molecular study of oncogenic transformation. He subsequently moved to Stanford University (USA) to do his Post Doc studying neural stem cells. Upon his return to the Netherlands he continued the study of adult stem cells in the group of Prof Hans Clevers at the Hubrecht Institute in The Netherlands. In the group of Hans Clevers he was part of the team that developed the breakthrough technology that allowed the expansion of adult stem cells. The so-called Organoid Technology became the basis of the non-profit company ‘Hubrecht Organoid Technology’ (HUB) of which he is currently the CEO.

Robert Vries in depth speaker interview can be downloaded on the conference website http://www.3D-cellculture.com/PR2 in the ‘download centre', and below is a snippet of the exclusive interview.

What is the greatest challenge for you to personally overcome within the 3D Cell Culture field currently?
‘The key obstacles have been two-fold. Firstly, there are the technical challenges: organoid technology is an advanced cell line technology, and it brings with it the issues of being less readily reproducible in the lab. Fundamentally, if the technical conditions cannot be aligned there will be a lower success rate. This challenge has been overcome as companies have developed better reagents and more robust protocols when using organoid technology.’

How would you like to see the 3D Cell Culture market develop in the future and where do you think the biggest growth area will be in the next few years?
‘In the last 10 years the 3D Cell Culture market has seen consistent growth, and I foresee that this trend will continue. The most significant growth will be in the application of organoid technology to clinical trials, and it is here in which they have the potential to do something new. We have seen that organoids can be used in a stage called the ‘pre-clinical clinical trial’, and if successful we could see organoid technology take over an entire portion of the clinical trial space – ultimately making drug trials more efficient and less costly.’

Registration is FREE for all active Pharmaceutical Professionals and vendors/Commercial Firms only £499, visit http://www.3D-cellculture.com/PR2

For delegate and group bookings, please contact Connor Marshall or call +44 (0)20 7827 6744.

Sponsored by Celvivo
For sponsorship enquiries contact Alia Malick on +44 (0)20 7827 6164 or amalick@smi-online.co.uk

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk

3D Cell Culture Conference 2021
Conference: 10th – 11th February 2021
Virtual Conference: Online Access Only
http://www.3D-cellculture.com/PR2
#SMi3DCellCulture

— ENDS –
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Simi Sapal
SMi Group
+442078276000
email us here


Source: EIN Presswire

Glove and Apron Dispenser Market 2020 Key players, Global Trend, Industry Size, Price and Opportunities Forecast to 2025

Glove and Apron Dispenser -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025

PUNE, MAHARASHTRA, INDIA, November 27, 2020 /EINPresswire.com/ — Glove and Apron Dispenser Industry

Description

Wiseguyreports.Com Adds “Glove and Apron Dispenser -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025” To Its Research Database

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

This report contains opportunities, strengths, threats, and weaknesses (SWOT) analysis for this market. They have taken many aspects into account for analysis, including sales volume, revenue level of the last few years, product demands, customer retention, etc. A majority of information has been collected from primary sources, and analysts have taken effective samples. As the market size is large, analysts have taken large sample sizes from different regions of the globe. They also calculated the Glove and Apron Dispenser Market's customer churns level because it plays a vital role in sales volume.

Global Glove and Apron Dispenser Industry 2020 Market Research Report Provide The Details About Industry Overview And Analysis About Manufacturing Cost Structure, Revenue, Gross Margin, Consumption Value And Sale Price, Major Manufacturers, Distributors, Industry Chain Structure, New Project Swot Analysis With Development Trends And Forecasts 2025.

The major players in the market include

Daniels
Angloplas
Shuttleworth Medical
Wybone
Pargon Products
Surey Pacific(Surey Tech)
Syspal

Request For Sample Report @ https://www.wiseguyreports.com/sample-request/6084013-global-glove-and-apron-dispenser-market-outlook-2021

Segment by Type
Non-Wall Mounted Glove and Apron Dispenser
Wall Mounted Glove and Apron Dispenser

Segment by Application
Hospital
Clinic
Other

Global Glove and Apron Dispenser Market: Regional Analysis

The report offers in-depth assessment of the growth and other aspects of the Glove and Apron Dispenser market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.

The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

Leave a Query @ https://www.wiseguyreports.com/enquiry/6084013-global-glove-and-apron-dispenser-market-outlook-2021

Table of Content

1 Glove and Apron Dispenser Market Overview
1.1 Product Overview and Scope of Glove and Apron Dispenser
1.2 Glove and Apron Dispenser Segment by Type
1.2.1 Global Glove and Apron Dispenser Production Growth Rate Comparison by Type 2020 VS 2026
1.2.2 Non-Wall Mounted Glove and Apron Dispenser
1.2.3 Wall Mounted Glove and Apron Dispenser
1.3 Glove and Apron Dispenser Segment by Application
1.3.1 Glove and Apron Dispenser Consumption Comparison by Application: 2020 VS 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Glove and Apron Dispenser Market by Region
1.4.1 Global Glove and Apron Dispenser Market Size Estimates and Forecasts by Region: 2020 VS 2026
1.4.2 North America Estimates and Forecasts (2015-2026)
1.4.3 Europe Estimates and Forecasts (2015-2026)
1.4.4 China Estimates and Forecasts (2015-2026)
1.4.5 Japan Estimates and Forecasts (2015-2026)
1.5 Global Glove and Apron Dispenser Growth Prospects
1.5.1 Global Glove and Apron Dispenser Revenue Estimates and Forecasts (2015-2026)
1.5.2 Global Glove and Apron Dispenser Production Capacity Estimates and Forecasts (2015-2026)
1.5.3 Global Glove and Apron Dispenser Production Estimates and Forecasts (2015-2026)
1.6 Glove and Apron Dispenser Industry
1.7 Glove and Apron Dispenser Market Trends

7 Company Profiles and Key Figures in Glove and Apron Dispenser Business
7.1 Daniels
7.1.1 Daniels Glove and Apron Dispenser Production Sites and Area Served
7.1.2 Daniels Glove and Apron Dispenser Product Introduction, Application and Specification
7.1.3 Daniels Glove and Apron Dispenser Production Capacity, Revenue, Price and Gross Margin (2015-2020)
7.1.4 Daniels Main Business and Markets Served
7.2 Angloplas
7.2.1 Angloplas Glove and Apron Dispenser Production Sites and Area Served
7.2.2 Angloplas Glove and Apron Dispenser Product Introduction, Application and Specification
7.2.3 Angloplas Glove and Apron Dispenser Production Capacity, Revenue, Price and Gross Margin (2015-2020)
7.2.4 Angloplas Main Business and Markets Served
7.3 Shuttleworth Medical
7.3.1 Shuttleworth Medical Glove and Apron Dispenser Production Sites and Area Served
7.3.2 Shuttleworth Medical Glove and Apron Dispenser Product Introduction, Application and Specification
7.3.3 Shuttleworth Medical Glove and Apron Dispenser Production Capacity, Revenue, Price and Gross Margin (2015-2020)
7.3.4 Shuttleworth Medical Main Business and Markets Served
7.4 Wybone
7.4.1 Wybone Glove and Apron Dispenser Production Sites and Area Served
7.4.2 Wybone Glove and Apron Dispenser Product Introduction, Application and Specification
7.4.3 Wybone Glove and Apron Dispenser Production Capacity, Revenue, Price and Gross Margin (2015-2020)
7.4.4 Wybone Main Business and Markets Served
7.5 Pargon Products
7.5.1 Pargon Products Glove and Apron Dispenser Production Sites and Area Served
7.5.2 Pargon Products Glove and Apron Dispenser Product Introduction, Application and Specification
7.5.3 Pargon Products Glove and Apron Dispenser Production Capacity, Revenue, Price and Gross Margin (2015-2020)
7.5.4 Pargon Products Main Business and Markets Served

7.6 Surey Pacific(Surey Tech)

7.7 Syspal

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=6084013

Continued…           

Contact Us: Sales@Wiseguyreports.com Ph: +1-646-845-9349 (Us)  Ph: +44 208 133 9349 (Uk)

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349
email us here


Source: EIN Presswire

Corona in Kliniken und Pflegeheimen: Schutz für Pflegekräfte durch kontaktlose Patientenkommunikation per App

Pflegepersonal benutzt App.

Pflegepersonal benutzt App. Bild: National Cancer Institute on Unsplash

Eine App für kontaktlose Patientenkommunikation kann Kliniken und Pflegeheimen helfen, Infektionsrisiken zu senken – gerade auch zu Zeiten der Corona-Pandemie.

NEW YORK, USA, November 27, 2020 /EINPresswire.com/ — Digitale Patientenkontakte sorgen für besseren und sichereren Service.

Das Coronavirus hält die Welt weiter in Atem. Persönliche Kontakte zu vermeiden ist immer noch der wichtigste Faktor, um die COVID19-Pandemie einzudämmen. Denn das Virus ist noch lange nicht besiegt oder unter Kontrolle. Weltweite Maßnahmen zum Schutz vor Infektionen haben zwar Teilbereiche verbessert, jedoch steigen die Zahlen weiter bzw. sinken nicht auf ein ungefährliches Niveau.

Was bisher nicht in allen Berufen möglich ist: Kontakte verringern.

Um sich und andere zu schützen, ist zur Zeit nichts effektiver als persönliche Begegnungen zu vermeiden. Dies empfehlen Virologen, die Politik reagiert entsprechend. In den meisten Ländern der Welt gibt es sogenannte Lockdowns, teilweise von unbestimmter Dauer. Das soziale Leben ist dadurch erheblich eingeschränkt. Doch Menschen im Gesundheits- und Pflegebereich müssen unter erschwerten Bedingungen weiterarbeiten.

Jeder sollte sich auch im Beruf schützen können.

Genau hier liegt die Herausforderung, da wir nicht in allen Bereichen völlig auf Kontakte verzichten können. Natürlich geht das z. B. beim Einkaufen, bei Veranstaltungen, im öffentlichen Nahverkehr und bei vielen anderen Aktivitäten recht gut. Doch wie sieht die Situation insbesondere bei der Behandlung und Pflege von Patienten in Krankenhäusern und bei Bewohnern von Pflege- und Altenheimen aus?

Immer mehr Pflegekräfte, Ärzte und weiteres Fachpersonal infizieren sich während der Ausübung ihres Berufes.

Das kann für die Betroffenen gesundheitlich äußerst gefährlich sein. Zudem fallen sie durch die Krankheit unmittelbar oder wegen möglicher Quarantäne als Mitarbeiter aus. Hierdurch entsteht ein zusätzlicher erheblicher Mangel an Fachkräften. Ein gutes Beispiel ist Deutschland, schon seit Jahren wird ein Mangel an Fachkräften beklagt. Die anhaltende Pandemie verschärft diese Problematik massiv. Es ist jedoch unmöglich in diesen Bereichen Kontakte völlig zu vermeiden. Eine teilweise Reduktion wäre aber möglich.

Sofortmaßnahmen in der Digitalisierung können helfen, auch in Kliniken und Pflegeeinrichtungen die Ausbreitung des Virus zu unterbrechen.

Mit einfachen digitalen Mitteln – einer neuartigen App – können unnötige Kontakte dennoch auf ein humanes und sinnvolles Minimum reduziert werden. Oberste Priorität muss immer die reibungslose Betreuung der Patienten und Pflegebedürftigen sein, dabei muss besonders die ältere Generation ebenso geschützt werden. Sollte durch einen unnötigen Kontakt ein älterer oder vorerkrankter Mensch infiziert werden, wäre das Ziel klar verfehlt.

Bis alle geimpft sind, kann es dauern, dennoch kann gehandelt werden.

Selbst die Aussicht auf einen Impfstoff wird diese Problematik in absehbarer Zeit nicht lösen können, zu lange wird es dauern, einen hohen Prozentsatz der Bevölkerung zu impfen. Dies wurde bereits nachdrücklich seitens der Politik propagiert. Kontaktbeschränkungen, um das Infektionsrisiko zu senken, werden uns noch lange begleiten.

Eine App kann Kliniken, Alten- und Pflegeheimen helfen.

Kontaktlos mit Patienten und Bewohnern kommunizieren zu können, würde die Situation auf den Stationen und in Heimen erheblich entschärfen. Herkömmliche Messenger-Dienste sind darauf aber nicht ausgerichtet, auch nicht in Sachen Sicherheit im Gesundheitsbereich. Zudem kann nicht jeder damit umgehen. Um diese Probleme zu beseitigen, hat die Firma ClinicAll International eine digitale Applikation entwickelt, die speziell Pflegekräfte und ärztliches Personal unterstützt. Diese Communicator-App hilft, unnötige Kontakte zu vermeiden. Patienten und Bewohner können jederzeit mit dem Personal Kontakt aufnehmen, Wünsche äußern und Anfragen stellen.

Pflegekräfte sparen wertvolle Zeit und verringern die Anzahl möglicherweise infektiöser Kontakte.

Der Pflegebedürftige äußert sein Anliegen einfach über die intuitiv bedienbare App. Mögliche Anfragen sind bereits eindeutig vordefiniert, so dass sie mit wenigen Klicks ausgewählt werden können. Oder die Person fordert einen Videoanruf an. Fachkräfte können so festlegen, in welcher Reihenfolge sie die Patientenwünsche reibungslos abarbeiten. Dadurch entfallen unnötige Laufwege und Kontakte, ohne Pflegebedürftige zu vernachlässigen.

Infektionsrisiken zu senken, ohne dass die Pflege auf der Strecke bleibt, ist das Gebot der Stunde.

Gleichzeitig müssen Standards langfristig erhalten und verbessert werden. Informationen über die Communicator-App finden Sie auf der ClinicAll-Website.

Hermann Kamp
ClinicAll International Corporation
+1 212 5881752
email us here
Visit us on social media:
Facebook
LinkedIn


Source: EIN Presswire